While autologous iPSC-based cell therapies are patient-specific, allogeneic iPSC-based cell therapies use donor-derived cells as a starting material. In recent years, a greater number of allogeneic iPSC-derived cell therapies are being studied than autologous therapies. One of the advantages of allogeneic therapy is that a large number of doses can be generated simultaneously from a single batch of iPSCs and banked. [Read more…]
Century Therapeutics Raises $60 Million, Acquires Clade Therapeutics, and Expands Pipeline of Allogeneic, iPSC-Derived Cellular Therapies
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile
Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026
Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform
Newly expanded pipeline incorporates three additional preclinical-stage programs from Clade’s αβ iT platform spanning across cancer and autoimmune diseases
SCG Cell Therapy And A*STAR Launch Joint Labs To Advance iPSC Technology For Scalable GMP Manufacturing Of Cellular Immunotherapies
Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies.
Launch of the joint labs builds on existing license, research collaboration and Memorandum of Understanding between SCG Cell Therapy and A*STAR.
Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology
Panasonic to create a closed-system manufacturing device based on Shinobi’s innovative iPS-T cell platform and cutting-edge research at Kyoto University
Partnership aimed at significantly broadening accessibility of cell therapies to patients on a global scale
SAN FRANCISCO and KYOTO, Japan, April 18, 2024 — Shinobi Therapeutics, a biotechnology company developing a new class of immune evasive iPS cell therapies, today announced a partnership with Panasonic Holdings Corp and Kyoto University’s Center for iPS Cell Research and Application (CiRA). Through this strategic collaboration, the organizations aim to engineer a novel manufacturing platform to produce iPS-T cell therapies more efficiently and at lower cost than is possible with currently available technology. [Read more…]
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
Melbourne, Australia; 8 April 2024 – Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). [Read more…]
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 79
- Next Page »